Adial Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference
Adial Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference
CHARLOTTESVILLE, Va., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that Cary Claiborne, CEO of Adial Pharmaceuticals, will be participating in the H.C. Wainwright 25th Annual Global Investment Conference being held September 11-13, 2023 at the Lotte New York Palace Hotel in New York City.
弗吉尼亞州夏洛茨維爾，9月2023年05日(環球通訊社)--ADIAL製藥公司(納斯達克代碼：ADIL；ADILW)(“ADIAL”或“公司”)，一家臨床階段的生物製藥公司專注於開發治療和預防成癮及相關疾病的療法，該公司今天宣佈，Aial製藥公司的首席執行官卡裡·克萊本將參加H.C.溫賴特25這是一年一度的全球投資大會將於2023年9月11日至13日在紐約市樂天紐約皇宮酒店舉行。
Adial's presentation will be available on-demand to registered attendees via the conference platform beginning Monday, September 11, 2023 at 7:00 AM Eastern Time. A webcast of the Company's presentation can also be accessed at and on the investor relations section of company Adial's website at
從2023年9月11日(星期一)東部時間上午7：00開始，ADIAL將通過會議平臺向註冊與會者提供ADIAL的演示文稿。還可以通過公司Aial網站的投資者關系部分收看公司演示文稿的網路直播，網址為
Management will be participating in one-on-one meetings with qualified members of the investor community throughout the conference in New York City. To request a meeting, please contact adil@crescendo-ir.com.
在紐約舉行的整個會議期間，管理層將參加與合格投資者群體成員的一對一會議。如需預約，請聯繫adil@cresendo-ir.com。
About Adial Pharmaceuticals, Inc.
Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of treatments for addictions and related disorders. The Company's lead investigational new drug product, AD04, is a genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder (AUD) in heavy drinking patients and was recently investigated in the Company's ONWARD pivotal Phase 3 clinical trial for the potential treatment of AUD in subjects with certain target genotypes (estimated to be approximately one-third of the AUD population) identified using the Company's companion diagnostic genetic test. ONWARD showed promising results in reducing drinking in heavy drinking patients, and no overt safety or tolerability concerns. AD04 is also believed to have the potential to treat other addictive disorders such as Opioid Use Disorder, gambling, and obesity. Additional information is available at .
關於阿迪爾製藥公司
ADIAL製藥公司是一家臨床階段的生物製藥公司，專注於開發成癮和相關疾病的治療方法。該公司領先的研究新藥產品AD04是一種基因靶向的5-羥色胺-3受體拮抗劑，是用於治療酗酒患者酒精使用障礙(AUD)的治療劑，最近在該公司未來關鍵的第三階段臨床試驗中使用該公司的配套診斷基因測試對某些目標基因類型(估計約佔AUD人群的三分之一)的患者治療AUD的可能性進行了研究。進一步的研究顯示，在減少重度飲酒患者飲酒方面取得了有希望的結果，沒有明顯的安全性或耐受性問題。AD04還被認為有可能治療其他成癮性疾病，如阿片類藥物使用障礙、賭博和肥胖。欲瞭解更多資訊，請訪問。
Contact:
聯繫方式：
Crescendo Communications, LLC
David Waldman / Alexandra Schilt
Tel: 212-671-1020
Email: adil@crescendo-ir.com
Cresendo Communications，LLC
大衛·沃爾德曼/亞歷山德拉·希爾特
電話：212-671-1020
電子郵件：adil@cresendo-ir.com